2-(Difluoromethyl)-DL-ornithine
- CAS No.
- 70050-56-5
- Chemical Name:
- 2-(Difluoromethyl)-DL-ornithine
- Synonyms
- EFLORNITHINE;Eflornithine API;2-(Difluoromethyl)-DL-ornithine;alpha-Difluoromethylornithine hydrochloride;2,5-diamino-2-(difluoromethyl)valeric acid hydrochloride;2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride;2,5-bis(azanyl)-2-(difluoromethyl)pentanoic acid hydrochloride
- CBNumber:
- CB62130510
- Molecular Formula:
- C6H12F2N2O2
- Molecular Weight:
- 182.17
- MOL File:
- 70050-56-5.mol
- MSDS File:
- SDS
- Modify Date:
- 2023/5/4 17:34:41
2-(Difluoromethyl)-DL-ornithine Chemical Properties,Uses,Production
Antimicrobial activity
Cultured bloodstream trypomastigotes of T. brucei are relatively
insensitive, but high doses are effective against bloodstream
and CNS infections of T. brucei brucei and T. brucei
gambiense in rodents, provided a strong antibody response
is also present. Eflornithine entry into the CNS can be
enhanced with suramin. T. brucei rhodesiense
infections do not respond. Synergy with some arsenicals has
been demonstrated.
Eflornithine is active against P. falciparum in experimental
models and against Leishmania promastigotes and Giardia
lamblia in culture.
Acquired resistance
Acquired resistance in T. brucei gambiense in West Africa has not been reported. East African T. brucei rhodesiense strains are innately less sensitive. Reported treatment failures are thought to be associated with severity of disease.
Pharmaceutical Applications
An analog of ornithine, formulated as the hydrochloride for intravenous infusion. It is freely soluble in water.
Pharmacokinetics
Oral absorption: 55%
Cmax 10 mg/kg oral: c. 7 mg/L after 4 h
200 mg/kg intravenously: 15.9 mg/L (87.5 nmol/mL) (mean)
Plasma half-life: 3.3 h
Volume of distribution: 0.34 L/kg
Plasma protein binding: Very low
Renal clearance is 83%, with most eliminated unchanged.
In a study in Zaire the mean serum concentration in children
under 12 years old was half that of adults, probably due
to more rapid renal clearance. CNS penetration is good in
adult patients, with a CSF:plasma ratio of 0.91 at the end of
administration for 14 days. However, the CSF:plasma ratio
in children under 12 years old was 0.58. Relapses have been
recorded in patients in whom CSF levels dropped below
9 mg/L (50 nmol/mL) at the end of treatment.
Clinical Use
2-(Difluoromethyl)-DL-ornithine has been used speculatively for treatment of Pn. jirovecii infections in AIDS patients. Co-administration with oral nifurtimox has been added to the World Health Organization (WHO) List of Essential Medicines for second-stage sleeping sickness caused by T. brucei gambiense.
Side effects
Osmotic diarrhea and bone marrow suppression are common, and up to 50% of sleeping sickness patients develop leukopenia. Reversible anemia and thrombocytopenia have been observed. Convulsions and seizures, different from those observed in melarsoprol-induced encephalopathy, have been reported in 4–18% of treated sleeping sickness patients but not in patients treated for Pn. jirovecii pneumonia. This difference might be due to the CNS inflammation associated with sleeping sickness.
2-(Difluoromethyl)-DL-ornithine Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | China | 49391 | 58 | Inquiry |
| Hangzhou Heta Pharm & Chem Co., Ltd | 0571-81958055 | China | 133 | 54 | Inquiry |
| Sanover (Xiamen) Technology Co., Ltd | 059265188632; 13876246362 | China | 502 | 58 | Inquiry |
| Shaanxi Xihua Chemical Industry Co., Ltd | 17691182729 15529505138 | China | 9963 | 58 | Inquiry |
| Taizhou Xingming Pharmaceutical Co., Ltd | 0086-576-88516108 | China | 54 | 60 | Inquiry |
| CacheSyn Inc. | +1 (416) 996-8186 | United States | 696 | 50 | Inquiry |
| Alfa Chemistry | +1 (201) 478-8534 | United States | 6824 | 0 | Inquiry |
| AnCheng Pharmaceutical Co. | 86-0755-82713308 | China | 280 | 50 | Inquiry |
| Jiangsu Qingfen Pharmaceutical Co., Ltd. | 0755-82713308 | China | 259 | 61 | Inquiry |